Recommendations for Screening and Management of Late Effects in SCID Patients after Allogenic Hematopoietic Cell Transplantation (HCT): A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late

Publication Type:

Journal Article


Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2017)


Severe Combined Immunodeficiency (SCID) is effectively treated with HCT with overall survival approaching 90% in contemporary reports. However, survivors are at risk for development of late complications due to the variable durability of high quality immune function, underlying genotype of SCID, comorbidities due to infections in the pre- and post- transplant period and use of conditioning pre-transplant. An international group of transplant experts was convened in 2016 to review the current knowledge of late effects seen in SCID patients following HCT, and develop recommendations for screening and monitoring for late effects. This report provides recommendations for screening and management of pediatric and adult SCID patients treated with HCT.